SCHEMBL4263134

SCHEMBL4263134

O=c1oc(NCCCCCCCCCCCCc2ccccc2)nc2sccc12

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ELANE P08246 13/20 0.54
MAOB P27338 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
SIGMAR1 Q99720 1/20 0.39
ASAH1 Q13510 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4265868 1.00 ELANE (0.54) ELANEMAOBADORA2AADORA2BADORA1
SCHEMBL4262162 0.84 HTT (0.47) ELANE
SCHEMBL4260450 0.83 ELANE (0.62) ELANE
SCHEMBL4259215 0.83 ELANE (0.62) ELANE
SCHEMBL13950785 0.83 ELANE (0.62) ELANE
SCHEMBL4258278 0.83 ELANE (0.62) ELANE
SCHEMBL4263185 0.83 ELANE (0.62) ELANE
SCHEMBL10362973 0.82 ELANE (0.80) ELANE
SCHEMBL3453286 0.82 ELANE (0.80) ELANE
SCHEMBL13950772 0.80 ELANE (0.60) ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP claimed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US claimed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US claimed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US claimed
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP disclosed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US disclosed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US disclosed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US disclosed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US disclosed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US disclosed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US disclosed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity LPL, LIPE, LIPC ELANE 282/4885MAOB 223/4885ADORA2A 993/4885
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY LPL, LIPE, LIPC ELANE 282/4885MAOB 223/4885ADORA2A 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.